Does Orforglipron Interact With Antidepressants?

Orforglipron and antidepressants aren’t flagged as a named interaction pair on the FDA-approved FOUNDAYO label — but that doesn’t mean the combination is interaction-free. Orforglipron delays gastric emptying, a mechanism that can affect how any oral medication is absorbed, and the label documents that effect directly. Here’s what the label actually says, why antidepressants specifically aren’t singled out, and what to bring to your prescriber if you take both.

The mechanism: gastric emptying, not a named drug pair

Orforglipron is a GLP-1 receptor agonist, and like others in its class, it slows how quickly food and other stomach contents move into the small intestine — the site where most oral drugs get absorbed. Per the FOUNDAYO label on DailyMed, this delayed gastric emptying can change how fast, and in some cases how completely, a co-administered oral medication reaches the bloodstream.

The label demonstrates this with a clinical pharmacology study using acetaminophen (a standard test drug for measuring gastric-emptying effects, not a specific safety concern on its own): per the FOUNDAYO label, acetaminophen’s peak concentration (Cmax) dropped by about 28% after the first 0.8 mg orforglipron dose, with the effect diminishing as dosing continued. That’s the general phenomenon behind every interaction question involving orforglipron and another oral drug — antidepressants included. It’s a mechanism, not a list of banned combinations, and the magnitude shown here is for acetaminophen specifically, not a number that transfers directly to any antidepressant.

Semaglutide and tirzepatide products carry the same underlying gastric-emptying mechanism, per their MedlinePlus drug information pages — this isn’t an orforglipron-specific quirk, it’s a GLP-1 class effect that shows up across oral and injectable forms alike.

What the label actually singles out — and what it doesn’t

The FOUNDAYO label calls out a specific handful of categories where gastric-emptying effects matter enough to warrant explicit guidance:

Category	What the label says
Oral hormonal contraceptives	Switch to a non-oral method, or add a barrier method, for 30 days after starting orforglipron and 30 days after each dose increase
Antibiotics needing rapid absorption	Delayed gastric emptying could blunt how quickly they work
Drugs with a narrow therapeutic index	Steady-state levels could shift enough to matter clinically
Other GI motility-slowing drugs	Can potentiate orforglipron’s own gastric-slowing effect

Antidepressants as a class aren’t on that list. Most commonly prescribed SSRIs (like sertraline or escitalopram) and SNRIs (like venlafaxine or duloxetine) aren’t classified as narrow-therapeutic-index drugs, which is the category most likely to need dose or timing adjustments around a gastric-emptying effect. That’s a meaningful distinction from, say, oral contraceptives, which the label addresses head-on. If you want the fuller picture of what the label does flag across drug categories, Orforglipron Drug Interactions covers it in more depth.

Why “not named” isn’t the same as “cleared”

Absence from the label’s specific callouts doesn’t mean a combination has been studied and found safe — orforglipron’s clinical trials weren’t designed to test every possible co-administered drug, antidepressants included. It means the label’s authors didn’t find the general mechanism concerning enough, for that drug category, to warrant a specific instruction the way it did for oral contraceptives. Whether your particular antidepressant, at your particular dose, needs any adjustment or monitoring is exactly the kind of question a pharmacist can answer by checking your regimen directly — and it’s a better answer than anything a general article can offer.

If you’re on an antidepressant and starting orforglipron

A few practical steps, none of which involve changing either medication on your own:

• Tell both prescribers about the full combination. The clinician managing your antidepressant and the one prescribing orforglipron should each know about the other medication.
• Don’t stop your antidepressant to “avoid an interaction.” Some antidepressants can cause discontinuation symptoms if stopped abruptly. That decision belongs to the prescriber who manages that medication, not to a precaution taken preemptively.
• Watch for new or worsening GI symptoms early on, since orforglipron’s own side effects — nausea especially — tend to show up during the first weeks and with each dose increase. First Week on Orforglipron covers what’s typical during that window, and Managing Orforglipron Nausea has practical tips if it overlaps with GI effects from your antidepressant.
• Keep a current, complete medication list — antidepressant name, dose, and timing included — for every visit, not just the one where you start orforglipron.

Why this differs from the birth control instruction

It’s worth contrasting antidepressants with oral contraceptives specifically, since the FOUNDAYO label treats them so differently. For hormonal contraceptives, the label gives a concrete, universal instruction — add a barrier method or switch to a non-oral method for 30 days after starting or increasing orforglipron — because the consequence of a missed dose (an unintended pregnancy) is significant enough to warrant a blanket precaution regardless of the specific contraceptive product. See Orforglipron and Birth Control for the details.

Antidepressants don’t get that same blanket treatment, in part because the class is large and varied — SSRIs, SNRIs, and other mechanisms behave differently, most aren’t narrow-therapeutic-index drugs, and a missed or delayed dose of most antidepressants doesn’t carry the same immediate, universal consequence a missed contraceptive dose does. That’s a reasonable basis for the label’s silence on antidepressants as a category, but it’s still not the same as a study confirming your specific medication is unaffected.

What this article won’t do

It won’t tell you that orforglipron and your specific antidepressant are safe together, and it won’t tell you they’re not. That determination depends on the exact drug, dose, your other medications, and your health history — information only your prescriber and pharmacist have. It also won’t recommend switching, stopping, or adjusting either medication; those are clinical decisions, not something to infer from a drug-class mechanism described in general terms.

Bottom line

Orforglipron’s interaction potential comes from one mechanism — delayed gastric emptying affecting oral drug absorption — and the FDA-approved label singles out a small number of categories where that matters enough for specific guidance: oral contraceptives, antibiotics needing rapid absorption, narrow-therapeutic-index drugs, and other GI-motility-slowing medications. Antidepressants aren’t on that list, but that’s not the same as a guarantee of no interaction for your specific prescription. Bring your full medication list, antidepressant included, to your prescriber and pharmacist before starting orforglipron.

For the broader interaction picture beyond antidepressants, see Orforglipron Drug Interactions, and for the basics of how orforglipron is taken day to day, How to Take Orforglipron.